Curis (NASDAQ: CRIS) announced data presented from in vitro and in vivo studies for CUDC-427, an antagonist of inhibitor of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE